Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia.

Calcif Tissue Int · 2021 · PMC8064984 · PMID 33484279

Europe PMC DOI

hedged sentence

0.1676

closest p · 3.4× alpha

0.1676

boldest claim

The sentences

did not reach statistical significancep = 0 .1676not close (p > 0.1)

Between-group differences did not reach statistical significance at either week 40 (− 3.25, 95% CI − 7.86 to + 1.37; p = 0 .1676) or week 64 (− 1.08, 95% CI − 6.21 to + 4.06; p = 0 .6810) (Fig. 2 c).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.